Pulled Pain Pill, Opioid Rates Show Need For Research
Law360, New York (July 10, 2017, 10:31 PM EDT) -- Endo International PLC’s recent decision to yank its painkiller Opana ER from the market, following pressure from the U.S. Food and Drug Administration to stop sales of the abuse-linked drug and as prescriptions of opioids remain high in many parts of the country, points to the need for more research in treating both pain and opioid addiction.
The FDA took the step a month ago formally requesting the drugmaker withdraw a prescription opioid due to abuse risks, in a move attorneys say was not only unprecedented but especially unusual under a Republican administration. Although Opana ER, or oxymorphone hydrochloride, had been...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!